Drug Profile
Research programme: anti-messenger RNA vectors - Engevity
Alternative Names: Vigilant vectorLatest Information Update: 02 Apr 2007
Price :
$50
*
At a glance
- Originator University of Florida
- Developer Engevity
- Class
- Mechanism of Action RNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Myocardial infarction
Most Recent Events
- 15 Apr 2003 Preclinical trials in Myocardial infarction in USA (unspecified route)